ICSBP/IRF-8: Its regulatory roles in the development of myeloid cells

被引:166
作者
Tamura, T [1 ]
Ozato, K [1 ]
机构
[1] NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1089/107999002753452755
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferon (IFN) consensus sequence binding protein (ICSBP)/IFN regulatory factor (IRF)-8 is an IFNgamma-inducible transcription factor of the IRF family and regulates transcription through multiple target DNA elements, such as IFN-stimulated response element (ISRE), Ets/IRF composite element, and IFN-gamma activation site (GAS). ICSBP-/- mice are immunodeficient and susceptible to various pathogens. They have defects in the macrophage function, including the ability to induce interleukin-12 (IL-12) p40 and some IFN-gamma-responsible genes. In addition, ICSBP-/- mice develop a chronic myelogenous leukemia (CML)-like syndrome, where a systemic expansion of granulocytes is followed by a fatal blast crisis. ICSBP-/- mice harbor an increased number of myeloid progenitor cells, and the -/- progenitors preferentially give rise to granulocytes, although they cannot efficiently generate another descendant of the myeloid lineage, macrophages. Studies with myeloid progenitor cells have shown that ICSBP drives their differentiation toward macrophage, whereas it inhibits granulocyte differentiation. Furthermore, myeloid cells from ICSBP-/- mice are resistant to apoptosis. These results illustrate the mechanism by which the loss of ICSBP leads to immunodeficiency and CML-like syndrome and suggest ICSBP's critical role in the development of myeloid cells.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 65 条
[1]  
BARBEAU G, 1995, CIRCULATION S, V1, P1
[2]   MOLECULAR-INTERACTIONS BETWEEN INTERFERON CONSENSUS SEQUENCE BINDING-PROTEIN AND MEMBERS OF THE INTERFERON REGULATORY FACTOR FAMILY [J].
BOVOLENTA, C ;
DRIGGERS, PH ;
MARKS, MS ;
MEDIN, JA ;
POLITIS, AD ;
VOGEL, SN ;
LEVY, DE ;
SAKAGUCHI, K ;
APPELLA, E ;
COLIGAN, JE ;
OZATO, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :5046-5050
[3]   Assembly requirements of PU.1-Pip (IRF-4) activator complexes:: inhibiting function in vivo using fused dimers [J].
Brass, AL ;
Zhu, AQ ;
Singh, H .
EMBO JOURNAL, 1999, 18 (04) :977-991
[4]   Pip, a lymphoid-restricted IRF, contains regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1 [J].
Brass, AL ;
Kehrli, E ;
Eisenbeis, CF ;
Storb, U ;
Singh, H .
GENES & DEVELOPMENT, 1996, 10 (18) :2335-2347
[5]   Suppression of IL-12 transcription in macrophages following Fcγ receptor ligation [J].
Cappiello, MG ;
Sutterwala, FS ;
Trinchieri, G ;
Mosser, DM ;
Ma, XJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (07) :4498-4506
[6]   Interaction between interferon consensus sequence-binding protein and COP9/signalosome subunit CSN2 (Trip15) - A possible link between interferon regulatory factor signaling and the COP9/signalosome [J].
Cohen, H ;
Azriel, A ;
Cohen, T ;
Meraro, D ;
Hashmueli, S ;
Bech-Otschir, D ;
Kraft, R ;
Dubiel, W ;
Levi, BZ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39081-39089
[7]   IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNγ-responsive promoters in macrophages [J].
Contursi, C ;
Wang, IM ;
Gabriele, L ;
Gadina, M ;
O'Shea, J ;
Morse, HC ;
Ozato, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (01) :91-96
[8]   JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].
DARNELL, JE ;
KERR, IM ;
STARK, GR .
SCIENCE, 1994, 264 (5164) :1415-1421
[9]   Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia [J].
Deng, M ;
Daley, GQ .
BLOOD, 2001, 97 (11) :3491-3497
[10]   The genomic structure of the chicken ICSBP gene and its transcriptional regulation by chicken interferon [J].
Dosch, E ;
Zöller, B ;
Müller-Redmann, I ;
Nanda, I ;
Schmid, M ;
Viciano-Gofferge, A ;
Jungwirth, C .
GENE, 1998, 210 (02) :265-275